Mobile-Menu

Ireland: New Medicines AstraZeneca to Build 360 Million Dollar API Manufacturing Unit

Editor: Ahlam Rais

The advanced active pharmaceutical ingredient (API) manufacturing facility for small molecules will be established in Dublin, Ireland and is expected to transform the development and commercialization of new medicines.

Related Vendors

ILUDEST Destillationsanlagen GmbH
Glatt Ingenieurtechnik GmbH
EPC Group
AstraZeneca
The 360 million dollar planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs.
The 360 million dollar planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs.
(Source: AstraZeneca)

Cambridge/UK – AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company’s global supply network is fit for future growth.

The new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility.

The 360 million dollar planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs. The project, which will provide an important boost to the local economy and to the country’s life-sciences sector, was developed with the support and collaboration of Ireland’s investment agency, IDA Ireland.

The industry-leading, future proof design of the plant will permit the addition of capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides.

The investment program is expected to significantly reduce commercialization lead times, costs and introduce more sustainable manufacturing processes, contributing to the Company’s Ambition Zero Carbon program. The industry-leading, future proof design of the plant will permit the addition of capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides.

(ID:47689950)

Related content